对猫的氨酸激酶抑制剂进行范围审查:当前证据和未来方向
1IVC Evidensia Small Animal Clinic Hofheim, 65719 Hofheim am Taunus, Germany.
Animals : an open access journal from MDPI
|October 14, 2023
概括
氨酸激酶抑制剂 (TKIs) 在猫类瘤学中表现有前途,特别是对巨细胞瘤的托塞拉尼布酸盐. 需要进一步的研究来扩大TKI的应用,并解决猫癌治疗方面的知识差距.
科学领域:
- 兽医瘤学 兽医瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸激酶抑制剂 (TKIs) 已在人类和犬类癌症治疗中得到证实.
- 它们在猫类瘤学中的应用仍然有限,目前还没有批准用于猫的TKI.
研究的目的:
- 系统地审查猫类组织中氨酸激酶表达的研究.
- 为了评估体外和体内对TKIs在家猫的使用.
- 识别知识缺口和潜在的未来的标志,用于猫癌的TKI.
主要方法:
- 在三个电子数据库和参考列表中进行了全面的文献搜索.
- 纳入标准确定了139项相关研究.
- 分析的重点是氨酸激酶表达和TKI在猫类瘤和非瘤组织中的疗效.
主要成果:
- 通常研究的猫类瘤包括大细胞瘤 (MCTs),乳腺癌,状细胞癌和注射部位瘤.
- 托塞拉尼布酸盐显示出最有效的效果,特别是在对抗猫类MCT时.
- 乳腺癌显示了TKI治疗的潜力.
结论:
- 托塞拉尼布酸盐目前是猫类癌症,特别是MCT最有前途的TKI.
- 进一步的研究至关重要,以确定新的征兆,并弥合猫类瘤学的知识差距.
- 需要进行临床试验来验证TKI在猫的有效性和安全性.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K


